Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 12/20 | 0.54 |
| ▸ | MMP13 | P45452 | 9/20 | 0.54 |
| ▸ | MMP9 | P14780 | 7/20 | 0.54 |
| ▸ | MMP3 | P08254 | 6/20 | 0.54 |
| ▸ | MMP1 | P03956 | 4/20 | 0.54 |
| ▸ | MMP8 | P22894 | 2/20 | 0.54 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.48 |
| ▸ | MMP7 | P09237 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6773472 | 0.91 | MMP2 (0.53) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6774032 | 0.88 | MMP2 (0.58) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6767954 | 0.85 | MMP2 (0.57) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL7246126 | 0.84 | MMP2 (0.52) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6780751 | 0.84 | MMP2 (0.49) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6773372 | 0.84 | MMP2 (0.49) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL7495698 | 0.84 | MMP2 (0.49) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6772015 | 0.84 | MMP2 (0.47) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6771334 | 0.83 | MMP2 (0.48) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL7497507 | 0.83 | MMP2 (0.55) | MMP2MMP13MMP9MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6566381-B1 | For therapy of arthritis, cancer, cardiovascular disorder, skin disorder, ocular disorder, inflammation and gum disease | THE PROCTER & GAMBLE COMPANY | 2003-05-20 | — | — | US | claimed |
| JP-2002538146-A | — | — | 2002-11-12 | — | — | JP | claimed |
| EP-1165530-A2 | DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000051993-A2 | DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | claimed |
| US-6762198-B2 | SUCH AS 2-((4'-METHOXY-(1,1'-BIPHENYL)-4-YL)-SULFONYL)-AMINO-3-(2-PHENOXYMETHYL -(1,3)DIOXAN-2-YL)PROPIONIC ACID | THE PROCTER & GAMBLE COMPANY | 2004-07-13 | — | — | US | disclosed |
| US-20030225074-A1 | Dihetero-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-6566381-B1 | For therapy of arthritis, cancer, cardiovascular disorder, skin disorder, ocular disorder, inflammation and gum disease | THE PROCTER & GAMBLE COMPANY | 2003-05-20 | — | — | US | disclosed |
| EP-1165530-A2 | DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000051993-A2 | DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225074-A1 | Dihetero-substituted metalloprotease inhibitors | ADAM9, ADAM17, ADAM8 | MMP2 10/4885MMP13 42/4885MMP9 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.